Skip to main navigation

About

Who We Are

Management Team
Board of Directors
Program Partners

Pipeline

Cardiovascular
Oncology
Ophthalmology
Inflammatory Disease

Patients

A Message to Our Patients
Our Areas of Focus
Clinical Trials

Investors

News & Events

News Releases
Events
Presentations

Stock

Stock Quote & Chart
Analyst Coverage

Governance

Documents & Charters
Management Team
Board of Directors
Committee Composition
Board Diversity Matrix

Financials

SEC Filings

IR Resources

Investor FAQs
Email Alerts
Contact IR

Contact

English
Chinese, Simplified

News Releases

Year

July 17, 2023

LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023

July 12, 2023

LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

June 26, 2023

LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore

June 8, 2023

LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

June 6, 2023

LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China

June 1, 2023

LianBio to Participate in Upcoming Investor Conferences

May 11, 2023

LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023

LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China

April 26, 2023

LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients

April 21, 2023

LianBio Promotes Pascal Qian to Chief Commercial Officer

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 22

Print Page

Email Alerts

RSS Feeds

Contact IR

Connect with us on social media.

About

Who We Are Management Team Board of Directors Program Partners

Pipeline Cardiovascular Oncology Ophthalmology Inflammatory Disease

Patients A Message to Our Patients Our Areas of Focus Clinical Trials

Investors News & Events Stock Governance Financials IR Resources

Contact

© 2023 LianBio. All Rights Reserved.